PTEN and cancer: Therefore, it is important to selectively inhibit cancer-promoting SASPs while retaining the antitumor features of SASPs; for example, inactivation of STAT3 reduces protumorigenic SASP without affecting the expression of antitumorigenic chemoattractants in a PTEN-null prostate cancer model83.